Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
> Pharma China Web Edition
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Product/R&D News
2/27/2025
Novartis' NDA for BTK Inhibitor Remibrutinib Accepted by NMPA
2/27/2025
Akeso Initiates First-in-Human Phase 1 Trial for HER3-Targeting ADC AK...
2/27/2025
Biokin (SystImmune) Initiates First Autoimmune Clinical Trial for Tetr...
2/27/2025
Henlius Registers Phase 3 Trials for Keytruda and Yervoy Biosimilars
2/27/2025
IVIEW Thera Reports Positive Phase 1/2 Results for IVW-1001 Ophthalmic...
2/26/2025
Hengrui Reports Promising Results for Trastuzumab Rezetecan in HER2-Mu...
2/26/2025
YolTech Therapeutics Announces Positive Clinical Data for In Vivo Gene...
2/26/2025
In Vivo Gene Editing Product ART002 Achieves Saturation of Pharmacolog...
2/25/2025
BioCity's SC0062 Achieves Primary Endpoint in Phase 2 DKD Trial
2/25/2025
Ardelyx/Fosun'sTenapanor Approved for Hyperphosphatemia in CKD Dialysi...
2/25/2025
XellSmart Secures Second FDA IND Approval for iPSC-Derived ALS Therapy...
2/21/2025
Hengrui Medicine Advances Dual GLP-1/GIP Agonist HRS9531 with First Ph...
2/21/2025
MediLink's YL217 Received FDA Clearance of IND Application
2/20/2025
Ascletis Reports Positive Interim Results from U.S. Phase Ib Study of ...
2/18/2025
NovoCodex's ARX788 Demonstrates Efficacy in HER2-Positive Advanced Bre...
2/18/2025
BioKin Initiates Phase III Trial in China for BL-B01D1 in NSCLC
2/18/2025
Huadong Medicine Announces Positive Results from HDM1005 Clinical Tria...
2/17/2025
Betta Pharma's Xcovery Initiates EMA Approval Process for Ensartinib i...
2/17/2025
BioNTech Initiates Phase 1/2 Trial for BNT327 and BNT323 Combination i...
2/17/2025
CSPC's SYS6005 ADC Enters Phase I Clinical Trials in China
2/14/2025
China Approves Novo Nordisk's Semaglutide Injection for New Indication
2/14/2025
NMPA Approves Sinocelltech's Finotonlimab for R/M HNSCC
2/14/2025
Trinomab's TNM002: A New Passive Immunization Agent for Emergency Teta...
2/14/2025
NMPA Approves SciClone's Vibativ for Drug-Resistant Gram-Positive Infe...
2/13/2025
Jiangsu Recbio's Novel HPV Vaccine Trial Approved in China
2/12/2025
Lion TCR's Liocyx-M004 Receives FDA IND Approval for Phase 2 Trial
2/12/2025
CSPC Granted NMPA Approval for Herpes Zoster mRNA Vaccine Clinical Tri...
2/12/2025
Merck Registers Kelun's Nectin-4 ADC MK-3120 and Initiates Phase 1 Tri...
2/11/2025
IVIEW Reports Positive Phase 1/2 Results for IVW-1001 Ophthalmic Eyeli...
2/11/2025
BioKin Pharma's HER2 ADC BL-M07D1 Advances to Phase III in China
Page:
8
/
15
Total number of articles:
433
:
[First]
[<<]
[6]
[7]
[8]
[9]
[10]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Focus Articles
Expert Opinions
Interviews
Case Studies
Company Profiles
News in Focus
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit